HER2-negative Breast Cancer Clinical Trials in Houston, Texas
15 recruitingHouston, Texas
Showing 1–15 of 15 trials
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Breast CancerOvarian CancerCervical Cancer+6 more
Regor Pharmaceuticals Inc.63 enrolled4 locationsNCT07524322
Recruiting
Phase 2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 1
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Metastatic Breast CancerHER2-negative Breast CancerHormone Receptor-Positive Breast Cancer
BeOne Medicines120 enrolled15 locationsNCT06756932
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 2
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
HER2-negative Breast CancerER Positive Breast Cancer
The Methodist Hospital Research Institute28 enrolled1 locationNCT05305924
Recruiting
Phase 2
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
HER2-negative Breast Cancer Patients With Brain Metastases
Biostar Pharma, Inc.120 enrolled17 locationsNCT06764940
Recruiting
Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Breast NeoplasmsHER2-negative Breast CancerInvasive Breast Cancer+1 more
Atossa Therapeutics, Inc.87 enrolled15 locationsNCT05607004
Recruiting
Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting
Phase 1
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc.190 enrolled16 locationsNCT05508906
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
PRE-I-SPY Phase I/Ib Oncology Platform Program
Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226